NASDAQ: IKTInhibikase Therapeutics Inc Stock
$1.87+0.29 (+18.35%)
Updated Apr 24, 2024
IKT Price
$1.87
Fair Value Price
$0.39
Market Cap
$12.11M
52 Week Low
$0.79
52 Week High
$4.35
P/E
-0.52x
P/B
1.1x
P/S
26x
PEG
N/A
Dividend Yield
N/A
Revenue
$260.50k
Earnings
-$19.03M
Gross Margin
100%
Operating Margin
-7,304.73%
Profit Margin
-7,304.7%
Debt to Equity
0.32
Operating Cash Flow
-$18M
Beta
0.72
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
IKT Overview
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IKT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IKT ($1.87) is overvalued by 380.3% relative to our estimate of its Fair Value price of $0.39 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IKT ($1.87) is not significantly undervalued (380.3%) relative to our estimate of its Fair Value price of $0.39 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IKT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IKT due diligence checks available for Premium users.
Be the first to know about important IKT news, forecast changes, insider trades & much more!
IKT News
Valuation
IKT fair value
Fair Value of IKT stock based on Discounted Cash Flow (DCF)
Price
$1.87
Fair Value
$0.39
Overvalued by
380.30%
IKT ($1.87) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IKT ($1.87) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IKT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IKT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.52x
Industry
15.69x
Market
41.27x
IKT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.1x
Industry
5.86x
IKT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IKT's financial health
Profit margin
Revenue
$1.0
Net Income
-$4.2M
Profit Margin
-417,794,000%
IKT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IKT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$14.5M
Liabilities
$3.5M
Debt to equity
0.32
IKT's short-term assets ($14.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IKT's short-term assets ($14.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IKT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IKT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
-$2.1M
Financing
-$138.1k
IKT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IKT vs Biotech Stocks
Inhibikase Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.